


BIOGEN



PHARMACHEM INDUSTRIES LIMITED

CIN NO: L51100GJ1995PLC026702

(Formerly Known as SUN TECHNO OVERSEAS LIMITED)

Date:13.11.2021

To,
Department of Corporate Services
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Dear Sir/Madam,

Sub: Un-Audited Financial Result quarter and half year ended on 30th September 2021 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015


In compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith Un-audited financial result for quarter and half year ended on 30th September, 2021.

Kindly take the same on your record and oblige.

Thanking You.

Yours Faithfully,

For, **BIOGEN PHARMACHEM INDUSTRIES LIMITED**



DIRECTOR/AUTHORISED SIGNATORY

Biogen Pharmachem Industries Limited

Formerly known as Sun Techno Overseas Limited

CIN:- L65910GJ1995PLC026702

Regd. Office: Shop No. 8, First Floor, Makers - 1 Building, Jawahar Road, Rajkot - 360001

Email:- suntechnooverseas@gmail.com

Statement of Audited Financial Results for the Quarter & Half Year Ended September 30, 2021

Sl no.	Particulars	Quarter Ended			Six Months Ended		(Rs. In lacs)
		30-Sep-21	30-Jun-21	30-Sep-20	30-Sep-21	30-Sep-20	Year Ended 31 Mar 2021
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	INCOME						
(a)	Revenue From Operation	122.27	125.15	-	247.42	-	162.26
(b)	Other Income	(16.43)	-	-	(16.43)	-	(160.81)
	Total Income from Operations (Net)	105.84	125.15	-	230.99	-	1.45
2	EXPENSES						
(a)	Cost of material consumed	103.25	98.24	-	201.49	-	148.06
(b)	Changes in inventories of finished goods, work-in-progress, and stock-in-trade	-	-	-	-	-	-
(c)	Employee benefit expense	1.36	1.42	-	2.78	-	1.39
(d)	Finance Costs	-	-	-	-	-	-
(e)	Depreciation and amortization expense	-	-	-	-	-	-
(f)	Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	0.16	5.40	0.09	5.56	0.24	12.32
	Total Expenses	104.76	105.06	0.09	209.83	0.24	161.77
3	Profit / (Loss) from operations before exceptional items Tax (1-2)	1.07	20.09	(0.09)	21.16	(0.24)	(160.32)
4	Exceptional Items	-	-	-	-	-	-
5	Profit / (Loss) before Tax (3 ± 4)	1.07	20.09	(0.09)	21.16	(0.24)	(160.32)
6	Tax Expense	-	-	-	-	-	-
7	Net Profit / (Loss) after Tax (5 - 6)	1.07	20.09	(0.09)	21.16	(0.24)	(160.32)
8	Other Comprehensive Income (net of tax)	-	-	-	-	-	-
9	Total Comprehensive Income for the period (7 ± 8)	1.07	20.09	(0.09)	21.16	(0.24)	(160.32)
10	Paid-up equity share capital (Face Value of Rs.1/- each)	6,526.03	6,526.03	6,526.03	6,526.03	6,526.03	6,526.03
11	Other Equity	-	-	-	-	-	(1,111.75)
12	Earnings Per Share (of Rs. 1/- each) (not annualised):						
(a)	Basic	0.00	0.00	(0.00)	0.00	(0.00)	(0.02)
(b)	Diluted	0.00	0.00	(0.00)	0.00	(0.00)	(0.02)



Biogen Pharmachem Industries Limited

Formerly known as Sun Techno Overseas Limited

CIN:- L65910GJ1995PLC026702

Regd. Office: Shop No. 8, First Floor, Makers - 1 Building, Jawahar Road, Rajkot - 360001

Email:- suntechnooverseas@gmail.com

(Rs. in Lakhs)

Standalone Statement of Assets and Liabilities		As at 30th September, 2021	As at 31st March, 2021
	Particulars	Un-Audited	Audited
A	ASSETS		
1	Non-current assets		
	Property, plant and equipment	-	-
	Capital work-in-progress	-	-
	Other intangible assets	-	-
	Investments in subsidiaries, associates and joint ventures	-	-
	Financial assets		
	Investments	1,153.42	949.22
	Loans	4,273.97	4,220.04
	Other financial assets	-	-
	Income Tax assets (net)	-	-
	Deferred tax assets (net)	-	-
	Other non-current assets	-	-
	Sub-total - Non-Current Assets	5,427.39	5,169.26
2	Current assets		
	Inventories	-	-
	Financial assets		
	Investments	-	-
	Trade receivables	138.30	247.95
	Cash and cash equivalents	2.05	0.75
	Bank balances other than Cash and Cash equivalents above	0.06	-
	Loans, Current	1.06	1.06
	Other financial assets	-	-
	Other current assets	-	-
	Assets classified as held for sale	-	-
	Sub-total - Current Assets	141.47	249.76
	TOTAL - ASSETS	5,568.86	5,419.02
B	EQUITY AND LIABILITIES		
1	Equity		
	Equity Share capital	6,526.03	6,526.03
	Other equity	(1,090.59)	(1,111.75)
	Sub-total - Shareholders' funds	5,435.44	5,414.28
2	LIABILITIES		
	Non-current liabilities		
	Financial liabilities		
	Borrowings, non-Current	-	-
	Provisions	-	-
	Income tax liabilities (net)	-	-
	Other non-current liabilities	-	-
	Sub-total - Non-current liabilities	-	-
3	Current liabilities		
	Financial liabilities		
	Borrowings, Current	-	-
	Trade payables, Current	126.00	-
	Other financial liabilities	-	-
	Other current liabilities	7.42	4.74
	Provisions	-	-
	Current tax liabilities (net)	-	-
	Sub-total - Current liabilities	133.42	4.74
	TOTAL - EQUITY AND LIABILITIES	5,568.86	5,419.02

Biogen Pharmachem Industries Limited

Formerly known as Sun Techno Overseas Limited

CIN:- L65910GJ1995PLC026702

Regd. Office: Shop No. 8, First Floor, Makers - 1 Building, Jawahar Road, Rajkot - 360001

Email:- suntechnooverseas@gmail.com


Notes:

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 13, 2021.
- 2 The Statutory Auditors have carried out a limited review of the above financial result.
- 3 Company has only one segment and hence no separate segment result has been given.
- 4 The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.
- 5 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

By Order of the Board
For, Biogen Pharmachem Industries Limited

Place : Rajkot

Date : 13th November, 2021



Biogen Pharmachem Industries Limited

Formerly known as Sun Techno Overseas Limited

CIN:- L65910GJ1995PLC026702

Regd. Office: Shop No. 8, First Floor, Makers - 1 Building, Jawahar Road, Rajkot - 360001

STANDALONE STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED 30 SEPTEMBER 2021

(Rs. in Lakhs, unless otherwise stated)

Particulars	30.09.2021 Rupees	30.09.2020 Rupees
A. CASH FLOW FROM OPERATING ACTIVITIES:		
Profit before tax	21.16	0.24
Adjustment For :		
Share of (profit)/loss from investment in partnership firm	-	-
Depreciation/amortization on continuing operation	-	-
Pre-operating Expense	-	-
Interest expenses	-	-
Operating profit before working capital changes	21.16	0.24
Movement in Working Capital :		
Increase/(decrease) in Inventory	-	-
Increase/(decrease) in Trade receivables	109.65	-
Increase/(decrease) in Short Term Loan & Advances	-	-
Increase/(decrease) in Current Liabilities	2.68	-
Increase/(decrease) in Trade Payable	126.00	-
Increase/(decrease) in Other Current Assets	-	-
Direct taxes paid (net of refunds)	-	-
Net Cash Flow from Operating Activities(A)	259.49	0.24
B. CASH FLOW FROM INVESTING ACTIVITIES		
Investments in Equity Instruments	- 204.20	-
Purchase / Sale of Fixed Assets	-	-
Increase/(decrease) in Long Term Loan & Advances	- 53.93	-
Net Cash Flow from Investing Activities(B)	- 258.13	-
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceed (Repayment) from long term borrowing	-	-
Proceed (Repayment) from short term borrowing	-	-
Proceed from Preferential Warrants	-	-
Net Cash Flow from Financing Activities(C)	-	-
Net increase/(decrease) in cash & cash equivalents(A+B+C)	1.36	0.24
Cash and Cash equivalents (Opening Balance)	0.75	0.34
Cash and Cash equivalents (Closing Balance)	2.11	0.10

Previous year figure have been regrouped/ reclassified wherever necessary

As per our report of even date

For, Rishi Sekhri and Associates,

Chartered Accountants

FRN: 126216w

Rishi Sekhri

CA Rishi Sekhri

Partner

M.NO. 126656

Place: Mumbai

Date : 13th November, 2021



For and on Behalf of the Board

Director

Place: Rajkot

Date : 13th November, 2021



RISHI SEKHRI AND ASSOCIATES CHARTERED ACCOUNTANTS

GROUND FLOOR, BANDRA ARCADE BUILDING, OPP. RAILWAY STATION, BANDRA (WEST), MUMBAI - 400 050.
Tel.: 9820501848, 26419136, Email : rishisekhri@gmail.com

INDEPENDENT AUDITORS' REVIEW REPORT ON THE STANDALONE UNAUDITED FINANCIAL RESULTS FOR QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2021

To
The Board of Directors of
BiogenPharmachem Industries Limited
(Formerly known as Sun Techno Overseas Limited)
Rajkot

We have reviewed the unaudited standalone financial results of Biogen Pharmachem Industries Limited (Formerly known as Sun Techno Overseas Limited) ("the Company") for the quarter ended September 30, 2021 which are included in the accompanying 'Statement of Standalone Unaudited Financial Results for the quarter ended September 30, 2021 and notes thereon (together referred to as the 'Standalone Statement'). The Standalone Statement has been prepared by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the Listing Regulations, 2015).

This Standalone Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Standalone Statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standard of Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the Standalone Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other recognized accounting practices generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR, RISHI SEKHRI AND ASSOCIATES,
Chartered Accountants
FRN: 128216W


CA RISHI SEKHRI
PARTNER
MEMBERSHIP NO. 126656
PLACE: MUMBAI
DATE: 13.11.2021
UDIN: 21126656AAADWF8609

